SecBot SecBot
8-K ·Filed Jun 2, 2026

VERA

Vera Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001193125-26-252475
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The accelerated timeline for eGFR data (Q3 2026) and potential sBLA submission (Q4 2026) is a significant positive catalyst for VERA. Traders should monitor for the eGFR readout in Q3 2026, as positive results would de-risk the path to full approval and could drive substantial upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.26
T+0 close · Jun 2, 2026 · via day close
Latest settled
+17.79%
T+60 · $36.82
Vs SPY
+16.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $31.26entry
  2. T+1 · 6mo ago +0.03%α +0.75% · $31.27
  3. T+5 · 5mo ago +1.76%α +4.72% · $31.81
  4. T+20 · 5mo ago +36.47%α +38.03% · $42.66
  5. T+60 · 3mo ago +17.79%α +16.67% · $36.82

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy. eGFR results are now expected in Q3 2026, with a supplemental Biologics License Application for full approval planned in Q4 2026, pending results. This accelerates the potential path to full approval for the company's lead asset.

Key Facts

  • Aligned with FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy.
  • eGFR results now expected in Q3 2026.
  • Plans to submit supplemental Biologics License Application for full approval in Q4 2026, pending eGFR results.
  • Filing date: June 2, 2026.

Financial Impact

No specific financial figures provided; the event accelerates a key regulatory catalyst for the company's only pipeline asset.

Risk Factors

  • eGFR results may not support full approval, leading to significant downside.
  • Regulatory timelines could slip, delaying the sBLA submission.
  • Competing therapies in IgA Nephropathy could limit atacicept's commercial potential.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-252475
Document: 0001193125-26-252475-index-headers.html0001193125-26-252475
Document: 0001193125-26-252475-index.html0001193125-26-252475
Document: 0001193125-26-252475.txt0001193125-26-252475

Track record

25 reports on VERA

Performance horizon

12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (10h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026